Drug Discoveries & Therapeutics
Online ISSN : 1881-784X
Print ISSN : 1881-7831
ISSN-L : 1881-7831
Commentary
Linezolid for patients with multidrug-resistant tuberculosis/extensively drug-resistant tuberculosis in China
Peize ZhangJie TanYi LinHailin ZhangGuofang DengXiaoyou Chen
Author information
JOURNAL FREE ACCESS

2022 Volume 16 Issue 2 Pages 96-98

Details
Abstract

Linezolid has been one of the key anti-tuberculosis agents for the treatment of multidrug-resistant tuberculosis (MDR-TB)/extensively drug-resistant tuberculosis (XDR-TB). It used to be very expensive and was not covered by social insurance from local governments. Nevertheless, a growing number of patients in China received linezolid in their anti- MDR/XDR TB regimens over the past decade. Many scholars in China have reported their experience using linezolid to treat patients with MDR/XDR-TB. In view of this, existing evidence of the efficacy and safety of linezolid and problems faced by Chinese patients with MDR/XDR-TB are summarized here.

Related papers from these authors
© 2022 International Research and Cooperation Association for Bio & Socio-Sciences Advancement
Previous article Next article
feedback
Top